APHA Risk Management & Mitigation 2 — Questions and Answers
Question 1: A patient reports they fainted after a previous vaccination. Which pre-vaccination strategy best mitigates syncope risk?
- Administer the vaccine while the patient is standing to allow quick movement
- Have the patient sit or lie down for vaccination and observe for 15 minutes afterward (Correct answer)
- Withhold the vaccine and refer the patient to a physician
- Administer a reduced dose to lower the likelihood of a vasovagal response
Correct answer: Have the patient sit or lie down for vaccination and observe for 15 minutes afterward
Patients with a history of syncope should be seated or supine during vaccination and observed for at least 15 minutes to reduce injury risk from fainting.
Question 2: Under the National Childhood Vaccine Injury Act (NCVIA), which vaccines MUST have a Vaccine Information Statement (VIS) provided before administration?
- Only childhood vaccines covered by the Vaccines for Children program
- All vaccines covered by the VICP, including influenza, Td, and Tdap (Correct answer)
- Only vaccines on the childhood immunization schedule
- Any vaccine administered in a federally funded clinic
Correct answer: All vaccines covered by the VICP, including influenza, Td, and Tdap
The NCVIA requires VIS distribution for all vaccines covered by the Vaccine Injury Compensation Program (VICP), which includes adult vaccines like influenza, Td, and Tdap.
Question 3: A pharmacist accidentally administers a vaccine that requires IM injection via the subcutaneous route. What is the most appropriate immediate action?
- Repeat the dose immediately via the correct IM route
- Document the error, notify the patient, and consult current ACIP guidance on whether a repeat dose is needed (Correct answer)
- Reassure the patient that subcutaneous vaccines are equally effective
- File a VAERS report and administer a booster dose within 24 hours
Correct answer: Document the error, notify the patient, and consult current ACIP guidance on whether a repeat dose is needed
Administration errors should be documented and reported; ACIP guidance determines whether a repeat dose via the correct route is necessary.
Question 4: Which action is most important when a patient's vaccination record is unavailable and their immunization history is uncertain?
- Administer all recommended vaccines immediately to ensure coverage
- Draw titers for all common vaccines before proceeding
- Treat the patient as unvaccinated and follow the catch-up immunization schedule (Correct answer)
- Decline to vaccinate until official records are obtained
Correct answer: Treat the patient as unvaccinated and follow the catch-up immunization schedule
When records are unavailable, ACIP recommends treating the person as unvaccinated and following the age-appropriate catch-up schedule to minimize under-immunization risk.
Question 5: Latex-containing vial stoppers or syringe plungers present a risk for which patient population?
- Patients with sulfa drug allergies
- Patients with documented latex hypersensitivity (Correct answer)
- Patients who are immunocompromised
- Patients with egg allergy
Correct answer: Patients with documented latex hypersensitivity
Latex-sensitive patients may experience allergic reactions from contact with latex-containing vaccine packaging components and require latex-free alternatives.
Question 6: What does the term 'programmatic error' mean in the context of vaccine risk management?
- An adverse event caused by a defect in the vaccine's manufacturing process
- A vaccine-preventable disease outbreak due to low herd immunity
- An adverse event resulting from errors in storage, handling, or administration rather than the vaccine itself (Correct answer)
- A documentation error in the patient's vaccination record
Correct answer: An adverse event resulting from errors in storage, handling, or administration rather than the vaccine itself
Programmatic errors are avoidable adverse events caused by improper storage, handling, reconstitution, or injection technique rather than an inherent property of the vaccine.
Question 7: Which of the following best describes the purpose of the Vaccine Adverse Event Reporting System (VAERS) in risk management?
- To verify causal relationships between vaccines and adverse events before taking action
- To serve as a national passive surveillance system for detecting potential vaccine safety signals (Correct answer)
- To replace the need for pre-vaccination screening for contraindications
- To provide real-time alerts when a vaccine lot is recalled
Correct answer: To serve as a national passive surveillance system for detecting potential vaccine safety signals
VAERS is a passive surveillance system used to detect potential safety signals; it generates hypotheses rather than proving causation.
APHA Risk Management & Mitigation 2
A patient reports they fainted after a previous vaccination.
Which pre-vaccination strategy best mitigates syncope risk?